COVID Articles
Results from Moderna’s Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age.
The U.S. Department of Health and Human Services has founded the Office of Long COVID Research and Practice to lead the Long COVID response and coordination across the federal government. In addition, the National Institutes of Health launched Long COVID clinical trials through the RECOVER Initiative.
According to data, patients with autoimmune diseases or long COVID who used a personalized digital care program (DCP) developed by Mymee alongside other nonpharmacologic strategies were more likely to achieve better health-related quality of life scores.
The U.S. Department of Health and Human Services (HHS) has issued an amendment to the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19.
The U.S. Food and Drug Administration has amended the emergency use authorizations of the. Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
U.S. scientists have developed a new genomic test that can predict a patient's risk of developing severe COVID-19, an advance that could help doctors quickly begin tailored treatment.
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.
A new systematic review and meta-analysis conducted by U.S. and Nepalese collaborators supports the use of IVIG with glucocorticoids compared to IVIG alone.
Researchers at the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine are developing a COVID-19 vaccine using a conventional method that will make the production and distribution cheaper and more accessible.
Investigators found COVID-19 infection altered the mothers’ immunity at delivery, and gestational COVID-19 exposure alters the immunity of newborns.
A new study demonstrates how severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection could be associated with an autoimmune response and development of autoantibodies.
Transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population.
